At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
In Brief
A Phase 2 clinical trial evaluating Bimekizumab, Certolizumab pegol, and 1 other intervention for Ankylosing Spondylitis. Completed, enrolled 76 participants across 34 sites in 8 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesCzechia, Germany, Greece, Moldova, Netherlands, Poland, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartOct 2017
Primary CompletionMay 2020
TodayJul 2026
First PostedJul 12, 2017
Enrollment StartOct 4, 2017
Primary CompletionMay 25, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.0 years ago
Interventions
Bimekizumabdrug
One bimekizumab dose will be administered.
Certolizumab pegoldrug
Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
Placeboother
Placebo will be provided to maintain the blinding.